JP2023502251A - ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法 - Google Patents

ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法 Download PDF

Info

Publication number
JP2023502251A
JP2023502251A JP2022529287A JP2022529287A JP2023502251A JP 2023502251 A JP2023502251 A JP 2023502251A JP 2022529287 A JP2022529287 A JP 2022529287A JP 2022529287 A JP2022529287 A JP 2022529287A JP 2023502251 A JP2023502251 A JP 2023502251A
Authority
JP
Japan
Prior art keywords
disease
subject
fxr
compound
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502251A5 (https=
Inventor
ユンチ チェン
ウィン ラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2023502251A publication Critical patent/JP2023502251A/ja
Publication of JP2023502251A5 publication Critical patent/JP2023502251A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2022529287A 2019-11-20 2020-11-19 ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法 Pending JP2023502251A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962937964P 2019-11-20 2019-11-20
US62/937,964 2019-11-20
PCT/US2020/061257 WO2021102124A1 (en) 2019-11-20 2020-11-19 Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response

Publications (2)

Publication Number Publication Date
JP2023502251A true JP2023502251A (ja) 2023-01-23
JP2023502251A5 JP2023502251A5 (https=) 2023-11-09

Family

ID=75981072

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529287A Pending JP2023502251A (ja) 2019-11-20 2020-11-19 ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法

Country Status (7)

Country Link
US (1) US20220409631A1 (https=)
EP (1) EP4061377A4 (https=)
JP (1) JP2023502251A (https=)
KR (1) KR20220119367A (https=)
CN (1) CN114786678A (https=)
TW (1) TW202128200A (https=)
WO (1) WO2021102124A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI819307B (zh) * 2020-05-19 2023-10-21 吉亞生物科技股份有限公司 萜類化合物在治療或預防纖維化疾病中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311036A (zh) * 2015-11-26 2016-02-10 中国农业大学 樟芝酸h在防治药物性肝损伤中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9713605B2 (en) * 2011-11-18 2017-07-25 Simpson Biotech Co., Ltd. Ameliorative or preventive effect of Antrodia cinnamomea in arthritis, cartilage destruction, or chondrocyte death
CN103159732A (zh) * 2011-12-15 2013-06-19 台湾利得生物科技股份有限公司 一种聚乙炔化合物、含其中的萃取物及其应用
JP2014139153A (ja) * 2012-08-24 2014-07-31 Taiwan Antitumer Biotech Co Ltd 腫瘍の治療及び／又は予防における抗がん薬と組み合わせたアントシン誘導体
WO2015065983A1 (en) * 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
CN104606260B (zh) * 2014-12-25 2018-01-30 恩扬生物科技股份有限公司 牛樟芝子实体萃取物用于改善化疗副作用的用途
TWI623749B (zh) * 2015-04-30 2018-05-11 吳永昌 一種樟芝萃取物製備及分析方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105311036A (zh) * 2015-11-26 2016-02-10 中国农业大学 樟芝酸h在防治药物性肝损伤中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. ETHNOPHARMACOL., vol. 206, JPN6024040351, 2017, pages 31 - 39, ISSN: 0005582507 *
SCI. REP., vol. 8:17424, JPN6024040352, 2018, ISSN: 0005582508 *

Also Published As

Publication number Publication date
EP4061377A4 (en) 2023-11-29
CN114786678A (zh) 2022-07-22
EP4061377A1 (en) 2022-09-28
US20220409631A1 (en) 2022-12-29
TW202128200A (zh) 2021-08-01
KR20220119367A (ko) 2022-08-29
WO2021102124A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Chenxu et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis: A mechanism involving Toll-like receptor 4 and oxidative stress
RU2644635C2 (ru) Системы, способы и составы для лечения рака
CN114641293A (zh) 一种fgfr抑制剂的用途
US20130316994A1 (en) Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
JP2011509253A (ja) 抗菌ペプチド系に対する作動薬
CN101820765A (zh) 包含雄激素受体降解(ard)增强剂的组合物和预防性或治疗性治疗皮肤病与脱发的方法
CN102014890B (zh) 男性不育治疗剂
CN102046180A (zh) 用于免疫治疗的组合物和方法
CA2644933A1 (en) Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
US12318386B2 (en) Combination of XPO1 inhibitors and second agents for the treatment of prostate cancer
JP2023502251A (ja) ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法
US20030212130A1 (en) Creatine ester anti-inflammatory compounds and formulations
US20060002911A1 (en) Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity
KR101901001B1 (ko) PPAR-β 길항제를 포함하는 항암 효과 증진용 약학적 조성물
JP2011519946A (ja) １−メチルニコチンアミド類似体
RU2721409C1 (ru) Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови
CN107233340B (zh) 芳香环类药物在抑制恶性黑色素瘤关键转录因子方面的应用
Van Neerven et al. Systemic but not local administration of retinoic acid reduces early transcript levels of pro-inflammatory cytokines after experimental spinal cord injury
HK40077325A (en) Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
CN115607546A (zh) Isarubrolone C、包含Isarubrolone C的药物组合物及应用
US12447147B2 (en) Methods of treating, ameliorating, and/or preventing cancer using pyrvinium compositions
JP6706852B2 (ja) 細胞老化抑制剤
HK40123938A (zh) 用於治疗X-ALD的甲状腺β激动剂给药方案

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250428